[{"id":"de38c659-13cf-45fe-9cef-d1ffb1fba21f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02688712","created_at":"2021-01-18T13:06:46.618Z","updated_at":"2024-07-02T16:35:22.277Z","phase":"Phase 2","brief_title":"ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer","source_id_and_acronym":"NCT02688712","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • galunisertib (LY2157299) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/24/2016","start_date":" 03/24/2016","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-25"},{"id":"678d8ba2-1946-41e3-baad-604dd5949706","acronym":"","url":"https://clinicaltrials.gov/study/NCT02672475","created_at":"2021-01-18T13:01:45.641Z","updated_at":"2024-07-02T16:35:28.392Z","phase":"Phase 1","brief_title":"Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer","source_id_and_acronym":"NCT02672475","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • ER negative • PGR expression • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • ER negative • PGR expression • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • galunisertib (LY2157299)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2023-11-22"},{"id":"5bc6f575-e47f-45a8-9b3d-701f5f0db4f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02906397","created_at":"2021-01-29T07:13:11.508Z","updated_at":"2024-07-02T16:36:14.684Z","phase":"Phase 1","brief_title":"Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT02906397","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" CD4 • TGFB1","pipe":"","alterations":" ","tags":["CD4 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e galunisertib (LY2157299)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 03/30/2017","start_date":" 03/30/2017","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 07/21/2021","study_completion_date":" 07/21/2021","last_update_posted":"2022-03-25"},{"id":"09e15c9c-e287-4fad-a870-fd5bca457d88","acronym":"","url":"https://clinicaltrials.gov/study/NCT02423343","created_at":"2021-01-18T11:35:30.982Z","updated_at":"2025-02-25T14:35:29.707Z","phase":"Phase 1b/2","brief_title":"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma","source_id_and_acronym":"NCT02423343","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR • ALK • AFP","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK fusion • AFP elevation","tags":["EGFR • ALK • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK fusion • AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • galunisertib (LY2157299)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2021-09-09"},{"id":"be737b18-0f8e-4837-8699-13ec5fb6d2ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT01246986","created_at":"2021-01-17T17:47:45.498Z","updated_at":"2024-07-02T16:36:36.161Z","phase":"Phase 2","brief_title":"A Study of LY2157299 in Participants With Hepatocellular Carcinoma","source_id_and_acronym":"NCT01246986","lead_sponsor":"Eli Lilly and Company","biomarkers":" AFP • TGFB1","pipe":"","alterations":" ","tags":["AFP • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • Cyramza (ramucirumab) • galunisertib (LY2157299)"],"overall_status":"Completed","enrollment":" Enrollment 204","initiation":"Initiation: 03/30/2011","start_date":" 03/30/2011","primary_txt":" Primary completion: 06/06/2019","primary_completion_date":" 06/06/2019","study_txt":" Completion: 12/24/2019","study_completion_date":" 12/24/2019","last_update_posted":"2021-01-12"},{"id":"90e3f6c7-8f4e-4efc-8376-ded3912b721b","acronym":"EORTC1615","url":"https://clinicaltrials.gov/study/NCT03470350","created_at":"2021-01-18T17:06:13.499Z","updated_at":"2024-07-02T16:36:57.715Z","phase":"Phase 1/2","brief_title":"Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer","source_id_and_acronym":"NCT03470350 - EORTC1615","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Vectibix (panitumumab) • capecitabine • galunisertib (LY2157299)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/24/2018","start_date":" 08/24/2018","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2020","study_completion_date":" 06/01/2020","last_update_posted":"2019-07-24"},{"id":"3dd54b28-d3fd-4201-b4d1-d646fcc1df03","acronym":"","url":"https://clinicaltrials.gov/study/NCT01373164","created_at":"2021-01-18T05:37:33.714Z","updated_at":"2024-07-02T16:37:10.720Z","phase":"Phase 1b/2","brief_title":"A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer","source_id_and_acronym":"NCT01373164","lead_sponsor":"Eli Lilly and Company","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • galunisertib (LY2157299)"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2018-05-16"}]